Sakar Healthcare Ltd (SAKAR) AI Stock Analysis

• Market Cap: ₹11.43B
• Dividend Yield: N/A
• Average Volume (3M): 19.08K
• Price to Earnings (P/E): 22.2
• Beta (1Y): 0.56
• Revenue Growth: 24.20%
• EPS Growth: 55.01%
• Country: IN
• Employees: 325
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 4.61
• Shares Outstanding: 21,949,910
• 10 Day Avg. Volume: 18,950
• 30 Day Avg. Volume: 19,083
• PEG Ratio: 0.71
• Price to Book (P/B): 1.79
• Price to Sales (P/S): 2.88
• P/FCF Ratio: -37.75
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹605.00
• Price Target Upside: 48.81% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 66 Neutral
• Price Target: ₹562.00 ▲(38.24% Upside)
• Action: Reiterated Date: 02/10/26
• Date: Action: Reiterated 02/10/26

The score is primarily driven by solid financial momentum (revenue growth and improving EBIT margin) but is held back by profitability/cash-flow concerns (sharp gross margin compression and negative free cash flow). Technically, the trend is strong with the price above major moving averages, while valuation is a headwind due to the elevated P/E and no dividend yield.

Positive Factors

Consistent Revenue Growth

Sakar has delivered roughly 15% annual revenue growth across recent years, evidencing durable demand and distribution reach in domestic and export markets. Sustained top-line expansion supports scale economies, broader product adoption and provides a foundation for margin recovery and reinvestment over the next several quarters.

Negative Factors

Sharp Gross Margin Compression

A near-halving of gross margin is a structural concern that materially reduces the buffer to cover SG&A and other operating costs. If driven by cost inflation, pricing pressure or mix shifts, recovery could be slow; lower gross margins impair long-term profitability and limit the durability of operating leverage benefits.

Sakar Healthcare Ltd Business Overview & Revenue Model

Company Description

Sakar Healthcare Limited research, develops, manufactures, and markets pharmaceutical products in India. The company provides liquid orals, cephalosporin tablets, capsules, dry powder syrups, dry powder injections, liquid injectable SVP in ampoule...

Read more

Sakar Healthcare Limited research, develops, manufactures, and markets pharmaceutical products in India. The company provides liquid orals, cephalosporin tablets, capsules, dry powder syrups, dry powder injections, liquid injectable SVP in ampoule...

How the Company Makes Money

Sakar Healthcare primarily makes money by selling pharmaceutical finished-dosage formulations. Its revenue is generated from (1) branded and/or generic formulations sold into the Indian market via distributors/stockists and channel partners, and (...

Read more

Sakar Healthcare primarily makes money by selling pharmaceutical finished-dosage formulations. Its revenue is generated from (1) branded and/or generic formulations sold into the Indian market via distributors/stockists and channel partners, and (...

Sakar Healthcare Ltd Financial Statement Overview

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	2.04B	1.78B	1.54B	1.33B	1.28B	947.39M
Gross Profit	719.02M	427.91M	699.59M	598.12M	534.12M	432.46M
EBITDA	535.80M	509.44M	393.27M	378.12M	315.72M	237.73M
Net Income	195.05M	175.02M	116.71M	127.59M	152.43M	106.83M
Balance Sheet
Total Assets	4.49B	4.15B	3.89B	3.36B	2.68B	1.78B
Cash, Cash Equivalents and Short-Term Investments	2.16M	3.09M	4.66M	35.23M	71.36M	824.65K
Total Debt	718.62M	749.55M	793.52M	1.19B	928.62M	425.97M
Total Liabilities	1.45B	1.30B	1.26B	1.63B	1.40B	793.40M
Stockholders Equity	3.03B	2.85B	2.62B	1.73B	1.27B	984.52M
Cash Flow
Free Cash Flow	31.88M	-135.52M	-350.93M	-468.81M	-618.33M	-209.69M
Operating Cash Flow	305.87M	187.31M	244.67M	353.14M	356.99M	145.77M
Investing Cash Flow	-274.00M	-307.09M	-515.39M	-743.77M	-903.72M	-468.33M
Financing Cash Flow	-32.81M	-34.79M	274.45M	410.96M	320.33M	320.33M

Sakar Healthcare Ltd Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 406.55
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SAKAR, the sentiment is Positive. The current price of 406.55 is below the 20-day moving average (MA) of 526.32, below the 50-day MA of 479.95, and above the 200-day MA of 393.09, indicating a neutral trend. The MACD of 7.28 indicates Positive momentum. The RSI at 51.28 is Neutral, neither overbought nor oversold. The STOCH value of 33.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:SAKAR.

Sakar Healthcare Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VENUSREM	79 Outperform	₹12.34B	10.01	―	―	13.32%	218.38%
SAKAR	66 Neutral	₹11.43B	22.21	―	―	24.20%	55.01%
INDSWFTLAB	61 Neutral	₹11.46B	18.86	―	―	-37.70%	-19.79%
KILITCH	56 Neutral	₹4.66B	34.53	―	―	32.95%	67.39%
MEDICAMEQ	55 Neutral	₹3.07B	56.53	―	0.26%	-9.16%	49.09%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NECLIFE	48 Neutral	₹2.25B	7.63	―	―	-30.27%	-3470.06%

Sakar Healthcare Ltd Corporate Events